Healthcare
Live Price
Offline$11.87
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alfresa Holdings Corporation (ARHCF) is a Healthcare stock with a market cap of $2.16B. The stock last traded around $11.87 and up 0.0% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +3.6%, EPS growth of -4.3%, a dividend yield of 2.9%. What stands out right now is revenue +3.6%, EPS -4.3%, free cash flow -120.4% with operating margin 1.2% and ROIC 4.6%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 12.7 and price/sales 0.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ARHCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ARHCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ARHCF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ARHCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.6T
+0.7% YoY
FY Net Income
$24.5B
-23.9% YoY
Free Cash Flow
-$39.4B
-301.5% YoY
Revenue Growth
+3.6%
EPS Growth
-4.3%
Gross Margin
7.1%
Net Margin
1.1%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2961.1B | 2858.5B | 2696.1B | 2585.6B | 2603.3B |
| Gross Profit | 213.9B | 206.4B | 192.1B | 187.5B | 175.5B |
| Operating Income | 38.1B | 38.5B | 30.1B | 29.1B | 20.7B |
| EBITDA | 54.6B | 57.4B | 52.0B | 61.1B | 32.5B |
| Net Income | 27.4B | 29.6B | 25.8B | 32.2B | 24.5B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 177.1B | 213.8B | 160.1B | 180.4B | 170.3B |
| Total Assets | 1439.9B | 1447.6B | 1339.9B | 1304.0B | 1316.7B |
| Total Liabilities | 957.6B | 967.8B | 851.5B | 832.2B | 826.7B |
| Shareholder Equity | 481.8B | 479.6B | 488.1B | 471.6B | 489.7B |
| Total Debt | 35.5B | 34.9B | 3.9B | 5.0B | 6.2B |
| Net Debt | -141.5B | -178.8B | -156.3B | -175.4B | -164.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21.2B
-158.0% YoY
Capital Expenditures
18.2B
-7.2% YoY
Free Cash Flow
39.4B
-301.5% YoY
Key ratios
Gross Margin
7.1%
Operating Margin
1.2%
Net Margin
1.1%
ROE
6.9%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.